LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

Начало・Списък с акции・Celsion Corp

Celsion Corp

Отворен

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+480.37% upside

Celsion Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.05.2026 г., 22:54 ч. UTC

Печалби

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.05.2026 г., 23:17 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13.05.2026 г., 23:16 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13.05.2026 г., 23:15 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13.05.2026 г., 23:14 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13.05.2026 г., 23:02 ч. UTC

Пазарно говорене

Печалби

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13.05.2026 г., 22:59 ч. UTC

Пазарно говорене

Печалби

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13.05.2026 г., 22:24 ч. UTC

Печалби

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13.05.2026 г., 22:23 ч. UTC

Печалби

Xero FY International Organic Revenue Growth 25%>XRO.AU

13.05.2026 г., 22:23 ч. UTC

Печалби

Xero FY International Revenue Growth 47%>XRO.AU

13.05.2026 г., 22:22 ч. UTC

Печалби

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13.05.2026 г., 22:19 ч. UTC

Печалби

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13.05.2026 г., 22:19 ч. UTC

Печалби

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13.05.2026 г., 22:18 ч. UTC

Печалби

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13.05.2026 г., 22:16 ч. UTC

Печалби

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13.05.2026 г., 22:15 ч. UTC

Печалби

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13.05.2026 г., 22:15 ч. UTC

Печалби

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13.05.2026 г., 22:13 ч. UTC

Печалби

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13.05.2026 г., 22:12 ч. UTC

Печалби

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13.05.2026 г., 22:11 ч. UTC

Печалби

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13.05.2026 г., 22:11 ч. UTC

Печалби

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13.05.2026 г., 22:10 ч. UTC

Печалби

Xero Did Not Declare a Dividend>XRO.AU

13.05.2026 г., 22:10 ч. UTC

Печалби

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13.05.2026 г., 22:09 ч. UTC

Печалби

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13.05.2026 г., 22:00 ч. UTC

Печалби

Cisco to Shed Jobs for All-In AI Push -- Update

13.05.2026 г., 21:11 ч. UTC

Печалби

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Celsion Corp Прогноза

Ценова цел

By TipRanks

480.37% нагоре

12-месечна прогноза

Среден 15.67 USD 480.37%

Висок 25 USD

Нисък 10 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Celsion Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Celsion Corp през последните 3 месеца.

Финанси

Относно Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.